APYX חוב כולל להון Apyx Medical Corporation

This chart of the total debt-to-equity ratio for Apyx Medical (APYX) is 3.46. Apyx Medical develops plasma rejuvenation systems, maintaining its position in the aesthetics market through patents and FDA clearances. The growth of its clinic network is driven by the recruitment of sales agents while retaining a staff of lead engineers. Robotic assembly ensures high product quality, although the final stage of treatment always remains with the physician.

Apyx Medical (APYX) maintains strong pricing power in the aesthetic surgery market, enabling efficient debt management, as clearly illustrated by the debt-to-equity chart. This metric compares total liabilities against shareholder equity to determine the degree of financial leverage: a lower ratio indicates greater business autonomy and a reduced risk of bankruptcy amid revenue volatility.